Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)-Reference-Cited by-同舟云学术

Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

Published:2017-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Larkin James,Chiarion-Sileni Vanna,Gonzalez Rene,Rutkowski Piotr,Grob Jean-Jacques,Cowey C. Lance,Lao Christopher D.,Schadendorf Dirk,Ferrucci Pier Francesco,Smylie Michael,Dummer Reinhard,Hill Andrew,Haanen John,Maio Michele,McArthur Grant,Walker Dana,Rollin Linda,Horak Christine,Hodi F. Stephen,Wolchok Jedd D.

Publisher

American Association for Cancer Research

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study;Journal of Modern Oncology;2023-12-10

2. Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy;Cancers;2023-06-03

3. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma;BMC Cancer;2021-07-01

4. Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets;Cancers;2021-06-25

5. Targeting CTLA ‐4 in cancer: Is it the ideal companion for PD ‐1 blockade immunotherapy combinations?;International Journal of Cancer;2020-12-21